Paris, France-based venture capital firm Seventure Partners completed a new closing for its microbiome fund, which now totals €160m.
Health for Life Capital, which aims to anticipate the microbiome revolution in the fields of health and nutrition, has already invested in a specific portfolio of innovative companies in the field of the microbiome and nutrition, such as Enterome, LNC, Maat pharma, Eligo bioscience, Targedys, Micropharma and others.
Led by Isabelle de Cremoux, CEO and Managing Partner of Seventure, Health for Life Capital relies on a wide network of industrial partners (Danone, Tereos, Lesaffre, Bel, Tornier and Novartis Pharma) and experts such as INRA (Institut National de Recherche Agronomique), the Danish Technology Institute (DTI), and Chalmers University of Technology in Gothenburg.
Founded in 1997, Seventure invests in innovative digital businesses in France and Germany and in the life sciences field across Europe and North America. In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology and cleantech, and now the microbiome, nutrition, personalized medicine and food.
A subsidiary of Natixis Global Asset Management, the firm also makes investments in the field of diagnostics, biomarkers, drug delivery systems, lifestyle healthcare and services.
Its investments range between €500k and €10m per round, or up to €20m per company, from early to late stage.
Seventure had over €500m in assets under management as of the end of 2014.